Anti-hepatitis B virus efficacy of tendovir disoproxil fumarate in HIV-infected patients

被引:106
作者
Benhamou, Y
Fleury, H
Trimoulet, P
Pellegrin, I
Urbinelli, R
Katlama, C
Rozenbaum, W
Le Teuff, G
Trylesinski, A
Piketty, C
机构
[1] Hop La Pitie Salpetriere, Serv Hepatogastroenterol, F-75013 Paris, France
[2] CHU Bordeaux, Serv Virol, Bordeaux, France
[3] Cenbiotech, Dijon, France
[4] Hop La Pitie Salpetriere, Serv Malad Infect, Paris, France
[5] Hop Tenon, Paris, France
[6] Hop Europeen Georges Pompidou, Serv Immunol Clin, Paris, France
关键词
D O I
10.1002/hep.21055
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Tenofovir disoproxil fumarate (TDF) has shown in vitro activity against both HIV and hepatitis B virus (HBV). We retrospectively evaluated the efficacy of TDF (300 mg/d), administered as a part of anti-retroviral therapy, in a large cohort of HIV/HBV-coinfected patients. Sixty-five HIV/HBV-coinfected patients who received TDF for at least 6 months with serum HBV DNA levels above 2.3 log(10) copies/mL at TDF initiation and who had stored serum samples before and during TDF therapy were included. Serum HBV DNA was measured on stored samples. The median follow-up period was 12 (Q1-Q3: 8-17) months. Serum hepatitis B e antigen (HBeAg) was positive in 54 patients (83.1%). Fifty-two patients (80.0%) were receiving lamivudine (LAM) (150 mg twice a day), and 68.8% had documented LAM resistance at baseline. Among HBeAg-positive patients, the median reduction from baseline (8.17; Q1-Q3 = 7.30-8.30 log(10) copies/mL) of serum HBV DNA was 4.56 log(10) copies/mL (Q1-Q3 = 3.33-5-55) (P <.0001). In HBeAg-negative patients, serum HBV DNA decline from baseline (4.83; Q1-Q3 = 2.69-6.40 log(10) copies/mL) was 2.53 log(10) copies/mL (Q1-Q3 = 0.39-4.10). At the end of the study, HBV DNA became undetectable in 29.6% and 81.6% of the HBeAg-positive and HBeAg-negative patients, respectively. Serum HBeAg became negative in 4 patients, 2 of whom acquired serum hepatitis B e antibody. In conclusion, this retrospective analysis demonstrates the efficacy of TDF against wild-type, presumed precore mutants and LAM-resistant HBV when used as a part of anti-retroviral therapy in HIV-coinfected patients.
引用
收藏
页码:548 / 555
页数:8
相关论文
共 50 条
  • [1] Identification and characterization of mutations in hepatitis B virus resistant to lamivudine
    Allen, MI
    Deslauriers, M
    Andrews, CW
    Tipples, GA
    Walters, KA
    Tyrrell, DLJ
    Brown, N
    Condreay, LD
    [J]. HEPATOLOGY, 1998, 27 (06) : 1670 - 1677
  • [2] Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase
    Angus, P
    Vaughan, R
    Xiong, S
    Yang, HL
    Delaney, W
    Gibbs, C
    Brosgart, C
    Colledge, D
    Edwards, R
    Ayres, A
    Bartholomeusz, A
    Locarnini, S
    [J]. GASTROENTEROLOGY, 2003, 125 (02) : 292 - 297
  • [3] Ninety-six-week efficacy of combination therapy with lamivudine and tenofovir in patients coinfected with HIV-1 and wild-type hepatitis B virus
    Bani-Sadr, F
    Palmer, P
    Scieux, C
    Molina, JM
    [J]. CLINICAL INFECTIOUS DISEASES, 2004, 39 (07) : 1062 - 1064
  • [4] Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation
    Bartholomew, MM
    Jansen, RW
    Jeffers, LJ
    Reddy, KR
    Johnson, LC
    Bunzendahl, H
    Condreay, LD
    Tzakis, AG
    Schiff, ER
    Brown, NA
    [J]. LANCET, 1997, 349 (9044) : 20 - 22
  • [5] An algorithm for the grading of activity in chronic hepatitis C
    Bedossa, P
    Poynard, T
    [J]. HEPATOLOGY, 1996, 24 (02) : 289 - 293
  • [6] Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1
    Benhamou, Y
    Thibault, V
    Vig, P
    Calvez, V
    Marcelin, AG
    Fievet, MN
    Currie, G
    Chang, CG
    Biao, L
    Xiong, S
    Brosgart, C
    Poynard, T
    [J]. JOURNAL OF HEPATOLOGY, 2006, 44 (01) : 62 - 67
  • [7] Effects of lamivudine on replication of hepatitis B virus in HIV-infected men
    Benhamou, Y
    Katlama, C
    Lunel, F
    Coutellier, A
    Dohin, E
    Hamm, N
    Tubiana, R
    Herson, S
    Poynard, T
    Opolon, P
    [J]. ANNALS OF INTERNAL MEDICINE, 1996, 125 (09) : 705 - +
  • [8] EFFICACY OF LAMIVUDINE ON REPLICATION OF HEPATITIS-B VIRUS IN HIV-INFECTED PATIENTS
    BENHAMOU, Y
    DOHIN, E
    LUNELFABIANI, F
    POYNARD, T
    HURAUX, JM
    KATLAMA, C
    OPOLON, P
    GENTILINI, M
    [J]. LANCET, 1995, 345 (8946): : 396 - 397
  • [9] Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus.
    Benhamou, Y
    Tubiana, R
    Thibault, V
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (02) : 177 - 178
  • [10] Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study
    Benhamou, Y
    Bochet, M
    Thibault, V
    Calvez, V
    Fievet, MH
    Vig, P
    Gibbs, CS
    Brosgart, C
    Fry, J
    Namini, H
    Katiama, C
    Poynard, T
    [J]. LANCET, 2001, 358 (9283) : 718 - 723